Angiodynamics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Angiodynamics Inc (ANGO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Angiodynamics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 324M vs 246,339M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months), vs accelerating (+4.1%) for its tracked peer group.
- Growth: Angiodynamics Inc generated 8.1% revenue growth year over year in Q1 2026, vs 9.0% for its competitors combined.
- Profitability: Its -8.8% net margin compares with 6.4% for the peer group.
- Scale: Angiodynamics Inc ranks #86 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Angiodynamics Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.51M compares with $0.40M for the peer group (1.3x).
- Structure: Angiodynamics Inc operates in the following segments: Med Device, Med Tech.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ANGO Sales vs. its Competitors, Q1 2026
Angiodynamics Inc reported revenue growth of 8.09 % year on year in Q1 2026, below its competitors' combined revenue growth of 9.01 %.
With a net margin of -8.77 %, Angiodynamics Inc reported lower profitability than its competitors (6.35 %).
Angiodynamics Inc generated 0.13 % of the combined sales of its peer group, up from 0.13 % a year earlier.
API endpoints for this dataset
Angiodynamics Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Angiodynamics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Angiodynamics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Angiodynamics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Angiodynamics Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 8.1% for Angiodynamics Inc. Angiodynamics Inc's share of combined industry revenue moved from 0.07% to 0.07%, a gain of 0.00 percentage points.
Angiodynamics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Angiodynamics Inc | No | Yes | No | No |
| Competitors combined (37) | ||||
| High-Confidence Competitors (14) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ANGO Stock Performance relative to its Competitors
ANGO Stock Performance relative to High-Confidence Competitors
ANGO Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Livanova Plc | 282.9% | Outperformed |
| 2 | Atricure Inc | 282.9% | Outperformed |
| 3 | Adagio Medical Holdings inc | 282.9% | Outperformed |
| 4 | Becton Dickinson And Company | 282.9% | Outperformed |
| 5 | Orchestra Biomed Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Angiodynamics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Angiodynamics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Angiodynamics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Angiodynamics Inc |
507.21 | 323.78 |
 Johnson and Johnson |
687,517.91 | 99,335.00 |
 Abbott Laboratories |
191,969.10 | 48,229.00 |
 Medtronic Plc |
130,553.31 | 37,542.00 |
 Stryker Corp |
124,754.36 | 26,300.00 |
 Boston Scientific Corporation |
64,904.40 | 21,070.00 |
| SUBTOTAL | 1,424,546.46 | 322,825.94 |
Sign in to see all competitors of Angiodynamics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Angiodynamics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Angiodynamics Inc's Competitors Named by the Company
Competitive relationships identified from Angiodynamics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inari Medical | Company report | 85% |
| Medtronic | Company report | 85% |
| TeleFlex Medical | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Varian Medical Systems | Company report | 85% |
| Avinger Inc | Company report | 85% |
| Total Vein Systems | Company report | 85% |
| Cook Medical | Company report | 85% |
| Profound Medical | Company report | 85% |
| Becton Dickinson | Company report | 85% |
| Philips 8 Healthcare | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| EDAP TMS | Company report | 85% |
| Merit Medical | Company report | 85% |
| Terumo Medical Corporation | Company report | 85% |
| Medical Components, Inc. (MedComp) | Company report | 85% |
| Siemens Healthineers | Company report | 85% |
| Stryker Corporation | Company report | 85% |
| Penumbra, Inc. | Company report | 85% |
| Siemens Healthineers | Company report | 85% |
| Philips Healthcare | Company report | 85% |
| Smiths Group plc | Company report | 85% |
| Smiths Medical | Company report | 85% |
| BD Medical Technology | Company report | 85% |
| Renovorx Inc | Company report | 85% |
| Flex Ltd | Company report | 85% |
| Icu Medical Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Cardiovascular Systems Inc | Company report | 85% |
| Icecure Medical Ltd | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Abiomed Inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Vaso Corporation | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Streamex Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Angiodynamics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Angiodynamics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Angiodynamics Inc | Med Device 50.67 % |
| Johnson and Johnson | Oncology 29.93 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Angiodynamics Inc | 507 | 512,316 | -52,114 |
| Johnson and Johnson | 687,518 | 705,504 | 114,311 |
| Abbott Laboratories | 191,969 | 419,383 | 40,878 |
| Medtronic Plc | 130,553 | 395,179 | 55,463 |
| Stryker Corp | 124,754 | 469,643 | 64,696 |
| Boston Scientific Corporation | 64,904 | 357,119 | 59,220 |
| PEERS TOTAL | 1,424,039 | 397,787 | 44,924 |
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Angiodynamics Inc | United States 87.83 % |
| Johnson and Johnson | United States 58.90 % |
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Angiodynamics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Angiodynamics Inc ranks #86 of 218 companies by market capitalization in its industry, holding 0.04 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 606, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 162,645 | 13.42 % |
| 2 | Medtronic Plc | 130,990 | 10.81 % |
| 3 | Stryker Corp | 124,012 | 10.23 % |
| 4 | 3m Company | 98,566 | 8.13 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 86 | Angiodynamics Inc | 498 | 0.04 % |
Market cap and industry share for the rest of Angiodynamics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Angiodynamics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 81 | Tactile Systems Technology Inc | 611 | 6.62 % |
| 82 | Sight Sciences Inc | 583 | 83.93 % |
| 83 | Anteris Technologies Global Corp | 573 | 47.86 % |
| 84 | Avita Medical Inc | 527 | 356.37 % |
| 85 | Strata Critical Medical Inc | 1,234 | 12.3% |
| 86 | Angiodynamics Inc | 498 | -0.17 % |
| 87 | Mimedx Group Inc | 1,234 | 12.3% |
| 88 | Neuropace Inc | 1,234 | 12.3% |
| 89 | Carlsmed Inc | 1,234 | 12.3% |
| 90 | Cerus Corporation | 1,234 | 12.3% |
| 91 | Orchestra Biomed Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Angiodynamics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Angiodynamics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.56 % | 46.20 % (avg) | -45.6 pp |
| Operating Margin | -0.10 % | industry median | -5.8 pp |
| EBITDA Margin | 0.03 % | -6.66 % (avg) | +6.7 pp |
| Capital Intensity (Capex / Revenue) | - | 7.13 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Angiodynamics Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | 20.9x | 17.8x | +3.1x |
| P/B | 3.6x | 4.6x | -1.0x |
| Return on Equity | -0.19 % | industry aggregate | -14.68 % |
| Return on Invested Capital | - | -6.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Angiodynamics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -0.69 % | -14.82 % | -7.65 % | 11.87 % | 8.13 % | 0.05 % | -13.30 % | 7.45 % |
| Operating Margin | 4.25 % | -6.12 % | -63.74 % | -13.88 % | -10.10 % | -2.39 % | -83.85 % | -10.65 % |
| Return on Invested Capital | 1.21 % | -1.38 % | -16.12 % | -4.43 % | -3.62 % | -0.91 % | -55.00 % | -8.36 % |
| P/E | 25.2x | 10.5x | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Angiodynamics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Angiodynamics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Angiodynamics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 606 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Angiodynamics Inc's dedicated Suppliers and Customers pages, not here.
Angiodynamics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Angiodynamics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Angiodynamics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 5.8 points below the industry median.
- Return on equity 14.7 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Angiodynamics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Angiodynamics Inc | 0.66 | 2.28 | - |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbott Laboratories | 0.36 | 1.45 | 0.53 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
Sign in to see all peers for Angiodynamics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Angiodynamics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Angiodynamics Inc | Q3 2026 | +8.1 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbott Laboratories | Q3 2026 | +14.5 % | -44.0 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| PEERS TOTAL | +9.2 % | -37.3 % |
Sign in to see all peers for Angiodynamics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Angiodynamics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Angiodynamics Inc | Q3 2026 | -0.4 % | +103.0 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbott Laboratories | Q3 2026 | +10.9 % | +3.4 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
Sign in to see all peers for Angiodynamics Inc .
Angiodynamics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Angiodynamics Inc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbott Laboratories | 4.54% | 5.14% | 9.00% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
Sign in to see all peers for Angiodynamics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Angiodynamics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Angiodynamics Inc | - | 1.57 |
| Johnson and Johnson | 42.48 | 6.92 |
| Abbott Laboratories | 40.91 | 3.98 |
| Medtronic Plc | 298.79 | 3.48 |
| Stryker Corp | 34.54 | 4.74 |
| Boston Scientific Corporation | 18.97 | 3.08 |
| PEERS AVERAGE | 39.15 | 4.41 |
Sign in to see all peers for Angiodynamics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.